Timothy Perera

Timothy Perera

UNVERIFIED PROFILE

Are you Timothy Perera?   Register this Author

Register author
Timothy Perera

Timothy Perera

Publications by authors named "Timothy Perera"

Are you Timothy Perera?   Register this Author

19Publications

566Reads

7Profile Views

Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody.

Cancer Res 2016 09 30;76(17):5019-29. Epub 2016 Jun 30.

Molecular Therapeutics and Exploratory Research Laboratories at Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy. Department of Oncology, University of Torino Medical School, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-3107DOI Listing
September 2016

Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.

Oncotarget 2015 Jan;6(1):221-33

Candiolo Cancer Institute - FPO IRCCS, Italy. Department of Oncology, University of Torino, Italy.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381590PMC
http://dx.doi.org/10.18632/oncotarget.2771DOI Listing
January 2015

Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs.

Cancer Res 2014 Nov 12;74(22):6598-609. Epub 2014 Sep 12.

Department of Oncology, University of Torino Medical School, Candiolo, Torino, Italy. Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-0761DOI Listing
November 2014

CD74-NRG1 fusions in lung adenocarcinoma.

Cancer Discov 2014 Apr 27;4(4):415-22. Epub 2014 Jan 27.

1Department of Translational Genomics; 2Department I of Internal Medicine; 3Laboratory of Translational Cancer Genomics; 4Network Genomic Medicine, University Hospital Cologne, Center of Integrated Oncology Cologne-Bonn; 5Center for Molecular Medicine Cologne (CMMC); 6Cologne Center for Genomics (CCG); 7Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD); 8Department of Pathology, University Hospital Medical Center, University of Cologne; 9Blackfield AG; 10Max Planck Institute for Neurological Research; 11Thoracic Surgery, Lungenklinik Merheim, Kliniken der Stadt Köln gGmbH; 12Institute of Human Genetics, Cologne; 13Computational Molecular Biology Department, Max Planck Institute for Molecular Genetics, Berlin; 14Department of Prostate Cancer Research, Institute of Pathology; 15Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn; 16Institute of Pathology; 17Department of Internal Medicine II, Jena University Hospital, Friedrich-Schiller-University, Jena; 18Institute for Pathology Bad Berka, Bad Berka, Germany;19Division of Molecular Oncology, Aichi Cancer Center Research Institute; 20Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan; Departments of 21Surgery and22Pathology, St. Vincent's Hospital; 23Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;24Department of Pathology, 25CHU Grenoble Institut National de la Santé et de la Recherche Medicale (INSERM) U823, Institute Albert Bonniot, Grenoble-Alpes University, Grenoble, France; 26Laboratory of Oncology IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo; 27Laboratory for Molecular Medicine and Biotechnology, University Campus Bio-Medico, Rome, Italy; 28Center for the Biology of Disease, VIB, Leuven; and 29Oncology Discovery, Janssen Research and Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0633DOI Listing
April 2014

MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.

Cancer Res 2014 Mar 21;74(6):1857-69. Epub 2014 Jan 21.

Authors' Affiliations: Institute for Cancer Research at Candiolo (IRCC), Center for Experimental Clinical Molecular Oncology; Department of Oncology, University of Torino, Candiolo, Torino, Italy; Aveo Oncology Inc., Cambridge, Massachusetts; and Janssen Research and Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2340-TDOI Listing
March 2014

A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors.

Int J Cancer 2012 Mar 30;130(6):1357-66. Epub 2011 May 30.

Laboratory of Molecular Pharmacology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, Candiolo, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.26137DOI Listing
March 2012

Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.

J Natl Cancer Inst 2011 Apr 4;103(8):645-61. Epub 2011 Apr 4.

IRCC-Institute for Cancer Research at Candiolo, University of Turin Medical School, Candiolo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djr093DOI Listing
April 2011

Tyrosine phosphorylation of tau by the SRC family kinases lck and fyn.

Mol Neurodegener 2011 Jan 26;6:12. Epub 2011 Jan 26.

MRC Centre for Neurodegeneration Research, Department of Neuroscience, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1750-1326-6-12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037338PMC
January 2011